Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID‐19 with B‐cell malignancies

This publication has 13 references indexed in Scilit:

• Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients
  Blood Advances, 2021
• Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  Nature Medicine, 2021
• Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
  Blood, 2021
• REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
  New England Journal of Medicine, 2021
• Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
  The Lancet, 2021
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
  New England Journal of Medicine, 2020
• Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
  Blood, 2020
• Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
  Nature Microbiology, 2020
• Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  Science, 2020
• Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
  The Lancet, 2020